PETACH TIKVA, Israel,
Nov. 18, 2014 /PRNewswire/
-- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a
biotechnology company advancing a pipeline of proprietary small
molecule drugs that address cancer and inflammatory diseases, today
announced several upcoming and near-term milestones on its CF101
and CF102 indications for liver cancer, rheumatoid arthritis,
psoriasis, glaucoma and the development of a commercial biomarker
blood test kit for the A3 adenosine receptor (A3AR).
The Company believes that it is on the cusp of reaching several
significant milestones in its studies, with respect to CF102 for
the treatment liver cancer and CF101 with respect to the
treatment of rheumatoid arthritis, psoriasis and glaucoma. The
below near-term key events provide an outlook of Can-Fite's
objectives and potential for increased growth.
Key Milestones for 2014/2015:
CF101
- Q4 2014 - Planning Phase III trials for rheumatoid arthritis
following the release of positive Phase II study results.
- Q1 2015 – Announce data for Phase II/III trial for psoriasis
with 300 patients for which Can-Fite has already received positive
interim data from the first 100 patients .
- Q2/Q3 2015 – Announce data for the Phase II study for glaucoma
with 88 patients.
CF102
- Q4 2014 - Patient enrollment has commenced for a Phase II trial
in Israel, Europe and the U.S. for the treatment of
patients with advanced liver cancer as a second line therapy.
Biomarker
- Q4 2014 - A3AR predictive biomarker blood test kit which will
have commercial applications. The commercial kit is designed to be
used prior to treatment to help identify an individual patient's
responsiveness to the Company's drugs, providing more personalized
medicine.
- The U.S. Patent and Trademark Office previously issued a patent
for the utilization of A3AR as a biomarker to predict patient
response to CF101 in autoimmune inflammatory indications.
"We are very excited at the opportunity of potentially receiving
further validation on our drug candidates which represents
significant steps forward in our commitment to delivering
treatments to patients. We hope to see this come to fruition upon
conclusion of our psoriasis, liver cancer and glaucoma trials."
stated Can-Fite CEO Dr. Pnina
Fishman.
Can-Fite's leading proprietary compounds, CF101 and CF102, are
centered on multi-billion dollar market opportunities. According to
GlobalData, the psoriasis drug market is forecasted to grow from
$3.6 billion in 2010 to $6.7 billion by 2018, while the rheumatoid
arthritis drug market according to independent business information
provider visiongain, is predicted to generate revenues of
$38.5 billion by 2017. GIA projects
that the global liver cancer drugs market will exceed $2 billion by 2015 and GlobalData projects that
the glaucoma market to top $3 billion
by 2018.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an
advanced clinical stage drug development company with a platform
technology that is designed to address multi-billion dollar markets
in the treatment of cancer and inflammatory diseases. The Company's
CF101 is in Phase II/III trials for the treatment of psoriasis and
the Company is preparing for a Phase III CF101 trial for rheumatoid
arthritis. Can-Fite's liver cancer drug CF102 is commencing Phase
II trials and has been granted Orphan Drug Designation by the U.S.
Food and Drug Administration. CF102 has also shown proof of concept
to potentially treat other cancers including colon, prostate, and
melanoma. These drugs have an excellent safety profile with
experience in over 1,200 patients in clinical studies to date. For
more information, please visit: www.can-fite.com
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite's expectations, beliefs or intentions regarding, among
other things, its product development efforts, business, financial
condition, results of operations, strategies or prospects. In
addition, from time to time, Can-Fite or its representatives have
made or may make forward-looking statements, orally or in writing.
Forward-looking statements can be identified by the use of
forward-looking words such as "believe," "expect," "intend,"
"plan," "may," "should" or "anticipate" or their negatives or other
variations of these words or other comparable words or by the fact
that these statements do not relate strictly to historical or
current matters. These forward-looking statements may be included
in, but are not limited to, various filings made by Can-Fite with
the U.S. Securities and Exchange Commission, press releases or oral
statements made by or with the approval of one of Can-Fite's
authorized executive officers. Forward-looking statements relate to
anticipated or expected events, activities, trends or results as of
the date they are made. Because forward-looking statements relate
to matters that have not yet occurred, these statements are
inherently subject to risks and uncertainties that could cause
Can-Fite's actual results to differ materially from any future
results expressed or implied by the forward-looking statements.
Many factors could cause Can-Fite's actual activities or results to
differ materially from the activities and results anticipated in
such forward-looking statements, including, but not limited to, the
factors summarized in Can-Fite's filings with the SEC and in its
periodic filings with the TASE. In addition, Can-Fite
operates in an industry sector where securities values are highly
volatile and may be influenced by economic and other factors beyond
its control. Can-Fite does not undertake any obligation to
publicly update these forward-looking statements, whether as a
result of new information, future events or otherwise.
Contact:
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
IRTH Communications
Robert Haag
canf@irthcommunications.com
1-866-976-4784
SOURCE Can-Fite BioPharma Ltd.